Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Bicara Therapeutics

Bicara Therapeutics (NASDAQ: BCAX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Bicara Therapeutics reported 57 open-market sales of 456,263 shares ($9.9m) and 1 open-market purchase of 300,000 shares ($4.8m), by 5 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Bicara Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
8 September 2026Cohlhepp RyanPresident, COO & Interim CEOOption exercise, 10b5-1 plan+17,500$3.79199,141Form 4
8 September 2026Cohlhepp RyanPresident, COO & Interim CEOOpen-market sale, 10b5-1 plan−14,058$22.77185,083Form 4
8 September 2026Cohlhepp RyanPresident, COO & Interim CEOOpen-market sale, 10b5-1 plan−3,442$23.43181,641Form 4
10 August 2026Cohlhepp RyanPresident and COOOption exercise, 10b5-1 plan+18,750$3.79200,391Form 4
10 August 2026Cohlhepp RyanPresident and COOOpen-market sale, 10b5-1 plan−18,750$27.98181,641Form 4
10 August 2026Mazumdar ClaireChief Executive OfficerOption exercise, 10b5-1 plan+10,000$3.79372,152Form 4
10 August 2026Mazumdar ClaireChief Executive OfficerOpen-market sale, 10b5-1 plan−10,000$27.98362,152Form 4
10 August 2026Hyep IvanChief Financial OfficerOption exercise, 10b5-1 plan+12,500$3.79142,355Form 4
10 August 2026Hyep IvanChief Financial OfficerOpen-market sale, 10b5-1 plan−12,500$27.97129,855Form 4
10 July 2026Mazumdar ClaireChief Executive OfficerOption exercise, 10b5-1 plan+10,000$3.79372,152Form 4
10 July 2026Mazumdar ClaireChief Executive OfficerOpen-market sale, 10b5-1 plan−9,972$28.42362,180Form 4
10 July 2026Mazumdar ClaireChief Executive OfficerOpen-market sale, 10b5-1 plan−28$29.68362,152Form 4
9 July 2026Cohlhepp RyanPresident and COOOpen-market sale, 10b5-1 plan−536$29.00181,641Form 4
8 July 2026Hyep IvanChief Financial OfficerOption exercise, 10b5-1 plan+12,500$3.79157,855Form 4
8 July 2026Hyep IvanChief Financial OfficerOpen-market sale, 10b5-1 plan−22,757$28.60135,098Form 4
8 July 2026Hyep IvanChief Financial OfficerOpen-market sale, 10b5-1 plan−4,413$29.82130,685Form 4
8 July 2026Hyep IvanChief Financial OfficerOpen-market sale, 10b5-1 plan−830$30.31129,855Form 4
8 July 2026Cohlhepp RyanPresident and COOOption exercise, 10b5-1 plan+18,750$3.79210,391Form 4
8 July 2026Cohlhepp RyanPresident and COOOpen-market sale, 10b5-1 plan−22,833$28.76187,558Form 4
8 July 2026Cohlhepp RyanPresident and COOOpen-market sale, 10b5-1 plan−4,306$29.80183,252Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Bicara Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.